TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Shusuke KawashimaTakashi InozumeMasahito KawazuToshihide UenoJoji NagasakiEtsuko TanjiAkiko HonobeTakehiro OhnumaTatsuyoshi KawamuraYoshiyasu UmedaYasuhiro NakamuraTomonori KawasakiYukiko KiniwaOsamu YamasakiSatoshi FukushimaYuzuru IkeharaHiroyuki ManoYutaka SuzukiHiroyoshi NishikawaHiroyuki MatsueYosuke TogashiPublished in: Journal for immunotherapy of cancer (2022)
The TIGIT/CD155 axis mediates resistance to ICIs in patients with melanoma with an inflamed TME, promoting the development of TIGIT blockade therapies in such patients with cancer.
Keyphrases